French women’s health company Womed recently announced significant advancements in the treatment of intrauterine adhesions (IUAs), a major cause of female infertility, with its product, Womed Leaf. The announcement came following the successful results of the PREG2 clinical trial, which were shared by Prof. Jean-Louis Benifla during the Choix des Armes conference in Marseille, France and suggest that Womed’s technology can help…
Biomedical company Femasys has successfully completed the first commercial procedure using its innovative FemaSeed intratubal insemination product. FemaSeed, which has received clearance from the U.S. FDA, employs a novel approach to enhance fertilization by precisely delivering sperm directly to the fallopian tube—the natural site of conception. This method is designed to be a primary therapeutic choice for those seeking pregnancy, offering reduced…
Two years have passed since Oya Care announced its $3 million seed funding round, secured from Susa Ventures, with additional investment from Brazilian entities Canary, Positive, and IKJ. In that time, the company has made significant progress, prompting us to sit down with Stephanie von Staa Toledo, Oya’s Founder & CEO, to discuss her journey as she works to position Oya as…
San Antonio-based fertility clinic network Pozitivf has recently raised $20 million in a funding round led by MonCap. This investment, among the most significant in the fertility space, is aimed at expanding Pozitivf’s reach and making fertility treatments such as IVF more affordable across the United States. Pozitivf’s service model offers IVF procedures starting at a cost of $7,995, which is significantly…
Reproductive health company Proov has recently launched the Proov Path to Pregnancy, a new at-home fertility treatment program offering a less invasive and more affordable option compared to traditional in-vitro fertilization (IVF). Amy Beckley, CEO and Founder of Proov, was inspired to create this program based on her personal challenges with infertility, aiming to provide easier access to effective fertility solutions. “In…
Inherent Biosciences and Genomic Prediction have announced a new commercial partnership to integrate Inherent Biosciences’ Epigenetic Sperm Quality Test (SpermQT), into Genomic Prediction’s clinical laboratory tests, focusing on male reproductive health. For a long time, the narrative around infertility has primarily focused on women, with limited progress in providing men with actionable insights into their fertility. The SpermQT test, developed by Inherent…
Fertilitywise has launched an online membership program designed to provide resources and a community for individuals and couples dealing with fertility issues. The program aims to offer educational articles and moderated discussion boards to support those undergoing fertility treatments. The platform addresses the need for clear information about fertility processes and treatments. It includes articles on various aspects of fertility, written in…
Singapore-based Zora Health has announced the launch of its integrated fertility care and financing platform, backed by $740K in funding. This investment round saw participation from notable angel investors, including Cheryl Goh (Founding CMO of Grab), Prajit Nanu (CEO of Nium), Alan Jiang (CEO of Beam), and Lisa Enckell (Venture Partner, Antler), as well as Asa Liden (former COO of Pitch.com). Venture…
